Ala-Septic Pharmaceutical Research

Growthbridge ventures is an Investor Relations and Marketing Outreach firm. The companies listed on this website and Portal are not an offer to the general public to purchase any form of securities. Every company listed on this website and Portal are listed for Investor Relations and marketing outreach, and should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the companies listed on this site, should they choose to engage in any form of investment. The information contained on these companies is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors and financial institutions and should not be used for any other reason or made available to any other person or entity without the prior written consent of Growthbridge ventures. The technology and process used on this website is protected by existing or pending patents owned by Growthbridge ventures. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Meet

Ala-Septic is a biotechnology company focused on developing patented, over-the-counter (OTC) botanical-based topical treatments for dermatological and immune-related conditions.

With a foundation in over 30 years of medical and cancer research, our flagship product, Ala-Septic Lotion, is a 98% botanical formulation with proven anti-viral, anti-fungal, and anti-bacterial properties. Our mission is to provide safe, effective, and affordable alternatives to chemical-based pharmaceuticals, making advanced skincare accessible to all.

We are committed to innovation, rapid development, and improving patient outcomes without the burden of side effects or high costs.

Problem They’re Solving

Conventional medications often rely on synthetic chemicals, leading to high costs and adverse side effects. Prescription-based access limits patient convenience and increases healthcare expenses.

Chronic skin and immune-related conditions lack affordable, natural, and effective long-term solutions. Many treatments require long-term use with diminishing returns and increased risk of resistance or complications.

Patients are demanding cleaner, more transparent ingredients and holistic alternatives to harsh pharmaceutical regimens.

Where They Are Headed

Expand our OTC product line into mainstream retail and international markets. Secure strategic partnerships for marketing, licensing, and distribution.

Advance our R&D pipeline targeting cancer, arthritis, and severe skin conditions with natural therapeutics. Build a trusted brand synonymous with botanical innovation and clinical-grade efficacy.

Position Ala-Septic as a leader in fast-track natural drug development with a focus on underserved conditions.

Opportunity Highlights

Disruptive innovation in dermatology and oncology: Our patented formula offers a non-invasive, natural alternative to surgery, chemo, and radiation.
Global regulatory approvals and export licenses: Ready for international expansion with FDA clearance and licenses for key emerging markets.
Broad therapeutic pipeline: Products in development for burns, arthritis, scalp conditions, and multiple cancer types including lung, liver, and leukemia.
Strong leadership and scientific credibility: Led by former Pfizer executives and experienced researchers with deep commercialization expertise.
Scalable business model with zero debt: Lean operations, proven product-market fit, and high-margin OTC sales position us for rapid growth and investor returns.

Management Team

Allen Cohen – Business Manager

Over 30 years of experience in medical and cancer research. Credited with two U.S. patents for a natural topical lotion that dissolves Melanoma skin cancer. Leads product innovation, clinical strategy, and intellectual property development.

Chris Bogle – Pharmaceutical Advisor

Brings 20+ years of pharmaceutical sales and marketing expertise, including 13 years at Pfizer. Specializes in market strategy, product positioning, and commercialization of dermatological and OTC products.

Sam Sandora – Media Manager

Oversees brand development, media outreach, and advertising campaigns. Skilled in digital marketing and public engagement, ensuring strong visibility and consumer awareness across platforms. Brings 30 years+ of management and media sales.

Key Metrics

Milestones

April 2012: Patents granted for dermatological treatments including Eczema, Psoriasis, and Melanoma (Stage-3)
Jan 2015: Patent application filed for Osteoarthritis Pain Crème and cartilage regeneration (expected by 2026)
2026 (Expected): Patent applications for severe burns, Seborrhea, Lung & Liver Cancer (Stage-4), and Leukemia